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Abstract
Background: The Memory Support Intervention was developed in response to evidence showing that: (1) patient
memory for treatment is poor, (2) poor memory for treatment is associated with poorer adherence and poorer
outcome, (3) the impact of memory impairment can be minimized by the use of memory support strategies and
(4) improved memory for treatment improves outcome. The aim of this study protocol is to conduct a confirmatory
efficacy trial to test whether the Memory Support Intervention improves illness course and functional outcomes. As
a “platform” for the next step in investigating this approach, we focus on major depressive disorder (MDD) and cognitive
therapy (CT).
Method/design: Adults with MDD (n = 178, including 20% for potential attrition) will be randomly allocated to CT +
Memory Support or CT-as-usual and will be assessed at baseline, post treatment and at 6 and 12 months’ follow-up
(6FU and 12FU). We will compare the effects of CT + Memory Support vs. CT-as-usual to determine if the new
intervention improves the course of illness and reduces functional impairment (aim 1). We will determine if patient
memory for treatment mediates the relationship between treatment condition and outcome (aim 2). We will evaluate
if previously reported poor treatment response subgroups moderate target engagement (aim 3).
Discussion: The Memory Support Intervention has been developed to be “transdiagnostic” (relevant to a broad range
of mental disorders) and “pantreatment” (relevant to a broad range of types of treatment). This study protocol
describes a “next step” in the treatment development process by testing the Memory Support Intervention for
major depressive disorder (MDD) and cognitive therapy (CT). If the results are promising, future directions will
test the applicability to other kinds of interventions and disorders and in other settings.
Trial registration: ClinicalTrials.gov, ID: NCT01790919. Registered on 6 October 2016.
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Background
Patients accurately recall only about one third of the
recommendations made during a physician visit [1–8]
and during a cognitive behavior therapy (CBT)
session [9, 10]. In one study, 25% of patients remem-
bered recommendations that were not made [1].
Recall is particularly poor for advice for health-
behavior change [11]. Perhaps not surprisingly, poor
memory for the content of treatment is associated
with poor adherence to medical treatments for
chronic conditions [12–16], which is known to be
associated with worse outcome [17]. Also, poor mem-
ory for CBT is associated with poorer outcome [10].
We have offered various explanations for these findings
[18]. First, even when memory is functioning optimally,
fallibility is possible at initial encoding, storage or retrieval
[19]. Second, a CBT treatment session is typically 50 min
long, covers complex information, and can elicit negative
emotion. Negative emotion is associated with attentional
biasing and narrowing, which impacts encoding [20].
Third, the odds are stacked against people learning, gener-
alizing and transferring knowledge to new situations; this
is known as the transfer of learning problem [21, 22].
Fourth, memory deficits and biases are common across
mental disorders [23–27] and memory deficits are
associated with poorer memory for treatment [28, 29].
The good news is that the impact of memory impair-
ment can be minimized. Memory encoding and reten-
tion can be markedly improved by the use of memory
support techniques. This has been demonstrated in
medical visits [13, 30], and among older adults [31] as
well as for people with memory impairments associated
with Alzheimer’s disease, vascular dementia [32] and
frontal lobe dysfunction [33].
We developed and tested the Memory Support Inter-
vention, which is designed to improve patient memory
for treatment. This approach is not intended to have a
direct effect on improving memory functioning per se.
The Memory Support Intervention was distilled from
the cognitive science and education literature based on
carefully honed criteria [18]. A small underpowered trial
has provided preliminary evidence that the intervention
exerts a measurable effect on patient memory for
treatment and demonstrates a clinical effect [34].
The Memory Support Intervention has been developed
to be “transdiagnostic” (relevant to a broad range of mental
disorders) and “pantreatment” (relevant to a broad range of
types of treatment). However, investigating these possible
broader applications seems premature without first estab-
lishing efficacy, which is the aim of the study described in
this paper. To create a platform for the “next step” in inves-
tigating the approach, we will recruit patients who meet
diagnostic criteria for major depressive disorder (MDD)
and focus on one biopsychosocial intervention—cognitive
therapy (CT). If the results are promising, future directions
will test the applicability to other kinds of interventions and
disorders and in other settings.
Why focus on MDD? First, MDD is prevalent and
causes impairment [35, 36]; second, there is a need to
improve treatments for MDD because a proportion of
patients do not recover and of those who do recover, the
majority relapse [37]; third, memory is poor in MDD
and is modifiable [38, 39]; fourth, preliminary data sug-
gest that improving memory for treatment in MDD
improves outcome [34, 40, 41].
Why focus on CT for MDD? CT for MDD is well articu-
lated and has been widely studied. Meta-analyses confirm
CT as a frontline treatment [42, 43]. Despite these impres-
sive outcomes, there is room for improvement [44, 45].
This study protocol addresses two additional consider-
ations. First, older age, lower intelligence and chronic
depression each predict poorer response to treatment
for depression, including CT [46]. Impairment in de-
clarative memory is also associated with poorer outcome
[47–50]. Moreover, fewer years of education has been
associated with a positive response to CT +Memory
Support relative to more years of education [34]. We
hypothesize that all of these poorer response groups
may derive special benefit from the Memory Support
Intervention. Hence, while we expect all patients to
benefit from the Memory Support Intervention, we
have planned analyses to determine if these subgroups
stand to gain the greatest advantage from experimen-
tal facilitation of memory for treatment. Second, there
is evidence that improved mood in MDD is associated
with improved declarative memory [51], although re-
mitted MDD patients still exhibit significant memory
deficits [23]. We have planned analyses to address
this potential confound.
Over a 4-year period, adults with MDD (n = 178,
including 20% for attrition) will be randomly allocated
to CT +Memory Support or CT-as-usual and will be
assessed at baseline, post treatment and at 6 and
12 months’ follow-up (6FU and 12FU). The first aim is to
assess whether the Memory Support Intervention (1)
improves the course of illness and (2) reduces functional
impairment. Compared to those receiving CT-as-usual,
we expect that patients receiving CT +Memory Support
will experience greater symptom reduction on measures
of course of illness, as defined by the American College of
Neuropsychopharmacology (ACNP) Task Force criteria,
and on measures of functional impairment. The second
aim is to evaluate whether patient memory for treatment
mediates the relationship between treatment condition
and outcome. Relative to CT-as-usual, we expect CT +
Memory Support to be associated with better treatment
outcome, and will be mediated by better patient memory
for treatment, measured by the Patient Treatment Recall
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Task. The third aim is to evaluate if previously reported
poor treatment response subgroups moderate target en-
gagement. We expect that the relationship between mem-
ory support dose and outcome will be positive and
stronger among those who are older, have lower IQ, have
more chronic depression, have poorer baseline declarative
memory performance and have fewer years of education.
Method/design
Study design and setting
This is a prospective randomized controlled study.
Adults (n = 178) who meet criteria for MDD will be
randomly assigned, in a 1:1 parallel group design, to CT
+Memory Support or CT-as-usual (see Fig. 1 for a flow
chart of the study design). Randomization is stratified by
age (≤49, 50 + years) and depression chronicity (< 2 years,
≥ 2 years) [46]. Participants receive a battery of outcome
measures pre-treatment and post-treatment (i.e., within
2 weeks after the final treatment session) and at 6 and
12 months’ follow-up. Additional assessments of patient
and therapist memory for treatment take place in weeks
4, 8, 12 and 16 of treatment for the mediation analysis.
The assessment team is blind to treatment allocation.
Randomization will be conducted using a computerized,
random-number generator where the planned stratified
randomization is a part of the generation of the alloca-
tion sequence. Only the project coordinators in charge
of randomization and of the Memory Support Rating
Scale (MSRS) scoring know the treatment allocation of
each participant. A Data Safety and Monitoring Board
(DSMB) will review the study every 6 months during the
active treatment phase. The Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT
2013) Checklist (see Additional file 1) and Figure (see
Fig. 2 Standard Protocol Item: Recommendation for
Interventional Trials diagram) are provided [52].
For participants who discontinue, the assessment team
will endeavor to collect all assessment data, prioritizing
the primary outcomes.
Participants
A total of 178 adults who meet the criteria will be re-
cruited. Recruitment will be conducted in the Bay Area,
CA, United States by clinician referral and advertisements.
Eligibility is assessed first by a phone interview and then,
if the individual is eligible after the phone interview, a
more detailed, in-person interview. To enhance represen-
tativeness and generalizability, the inclusion and exclusion
criteria are kept to a minimum.
Inclusion criteria
The inclusion criteria are:
 Age 18 + years
 Willing and able to give consent. Participants must
consent to being video-recorded (necessary for
MSRS scoring) and to NIMH data sharing1
 English language fluency
 Diagnosis of major depressive disorder (MDD), first
episode, recurrent or chronic according to the
Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5)
 Minimum score 26 or above on the Inventory of
Depressive Symptomatology, Self-Report (IDS-SR).
This cutoff denotes at least “moderate” depression
 If taking medications for mood, medications must be
stable for the past 4 weeks
Exclusion criteria
The exclusion criteria are:
 History of bipolar disorder
 History of psychosis or psychotic features
 Lifetime history of failure to respond to four or
more sessions of CBT/CT for depression
 Current non-psychotic disorder if it constitutes the
principal diagnosis and if it requires treatment other
than that offered in the project. “Principal” is defined
as the disorder currently most distressing and
disabling, using a widely accepted severity rating
scale capturing distress and interference (0–8, 4 +
indicates clinical severity)
 Moderate or severe substance use in the past
6 months where “moderate” is defined as 4–5
symptoms and “severe” is defined as 6 + symptoms
of those listed in DSM-5 for each of the substance-
related disorders
 Evidence of any medical disorder or condition that
could cause depression, preclude participation in
CT, or is associated with memory problems, that is
not currently stabilized and/or managed under the
care of a physician or the presence of an active and
progressive physical illness or neurological
degenerative disease
 Current suicide risk sufficient to preclude treatment
on an outpatient basis (assessed by the Columbia-
Suicide Severity Rating Scale) or current homicide
risk (assessed by our staff or referring treatment
provider)
 Pregnancy or breastfeeding
 Not able/willing to participate in and/or complete
the pre-treatment assessments
Excluding participants whose medications need to
be changed is neither feasible nor representative of
clinical practice [53]. Strategies to manage potential
medication confounds are: (1) medications must be at
Harvey et al. Trials  (2017) 18:539 Page 3 of 11
stable doses for 4 weeks prior to randomization and
(2) medication use and changes, along with participa-
tion in other treatments/therapy, will be recorded. All
medication decisions will ultimately rest with the
treating physician and participant.
Following the precedent set in prior research [54],
participants with a lifetime history of failure to re-
spond to four or more sessions of CBT for depression
will be excluded. Participants who have engaged in
moderate or severe substance use in the past 6 months
will also be excluded. “Moderate” substance use is
defined as four to five symptoms and “severe”
substance use is defined as six or more of the
symptoms listed in the DSM-5 for each of the
substance-related disorders.
Measures
The primary and secondary outcomes are presented in
Additional file 2. Additional file 3 lists all of the mea-
sures as well as the timing for administration. Except
where specified in Additional file 3, the measures de-
scribed below will be delivered at each assessment point.
In addition to demographics (age, contact information,
gender, race/ethnicity, family, education, employment,
living arrangements, government assistance, housing)
and assessment of medical history the following
measures will be administered:
Diagnostic
To evaluate current and past psychiatric disorders the
Structured Clinical Interview for DSM-5 (SCID) [55, 56]
Fig. 1 Standard Protocol Items: Anticipated patient flow for the randomized clinical trial
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will be administered along with the Longitudinal
Interval Follow-up Evaluation (LIFE) [57] to further
ascertain presence/absence of MDD, number and length
of mood episodes and remission, response, relapse,
recovery, recurrence and time to relapse or recurrence
(see Additional file 1 for definitions which are drawn
from the ACNP criteria [58]).
Symptomatic
The IDS-SR [59], a widely used self-report measure of
depression severity, as well as two subscales (ideation
and behavior) from the lifetime and current version of
the Columbia-Suicide Severity Rating Scale (C-SSRS)
[60–62], will be administered. The Quick Inventory for
Depression Symptomatology (QIDS) is administered
every treatment session [38] for clinical purposes (moni-
toring of suicide and depression symptoms).
Functional impairment
The World Health Organization Disability Assessment
Schedule 2.0 (WHODAS 2.0) [39] as well as the four-
question “Healthy Days” (CDC HRQOL-4) core module
developed by the CDC [63] will be administered.
IQ
The National Adult Reading Test (NART) [64] estimates
premorbid intelligence. The total number of errors are
calculated and used to derive an estimate of full-scale IQ
and verbal IQ.
Memory
The Patient Treatment Recall Task [10] and the
Generalization Task [65] are included as early indicators
of target engagement and the trajectory of recall and
learning over time. Classical tests of memory include a test
of declarative memory—the Episodic Face-Name Learning
Task [66–68]—which is the domain in which the most
profound declines in MDD are observed [69–74].
Working memory will be assessed via the N-Back [75]
because working memory aids the formation and reten-
tion of long-term declarative memories via attentive and
elaborative-rehearsal processes [76, 77].
Memory Support Rating Scale (MSRS) [78]
Selected treatment session video-recordings will be
coded using the MSRS to establish the dose of memory
support delivered.
Medication and other treatment tracking logs will be
used to record the additional treatments patients are
Fig. 2 Standard Protocol Items: SPIRIT Figure: Schedule of enrollment, interventions, and assessments
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receiving and any changes in those treatments through-
out the duration of the study.
Treatment credibility/expectancy is administered at
session 2, post-treatment, 6FU and 12FU via the
Credibility/Expectancy Questionnaire [79, 80].
Exploratory measures
As this is a relatively new program of research and we
wish to learn as much as possible, we have included the
following measures on a pilot/exploratory basis: Patient
Usefulness and Utilization of Cognitive Therapy Skills
Scale (delivered post treatment, 6FU and 12FU), the
Competencies in Cognitive Therapy Scale [81] (delivered at
post treatment, 6FU and 12FU), Patient Conceptualization
of Depression Task (delivered at the pre-treatment assess-
ment, post treatment and 6FU) and a Memory Support
Treatment Provider Checklist to be completed by the ther-
apists delivering CT +Memory Support (delivered during
weeks 4, 8, 12 and 16 of the treatment).
Treatments
Both treatments are comprised of 20–26 × 50-min
sessions conducted over 16 weeks.
CT-as-usual
CT was developed by Beck et al. [82] and has incor-
porated a number of innovations [83, 84]. Treatment
maneuvers are designed to identify, reality test, and
correct distorted beliefs and information processing
[82]. CT for MDD will be conducted according to the
standard manuals [82, 85, 86].
CT +Memory Support
The Memory Support Intervention is a manualized ad-
junctive treatment that will be delivered alongside CT-
as-usual. The Memory Support Intervention is designed
to improve patient memory for treatment. Distilled from
the cognitive science and education literature based on
carefully honed criteria [18], the Memory Support Inter-
vention is comprised of eight memory-promoting strat-
egies: attention recruitment, categorization, evaluation,
application, repetition, practice remembering, cue-based
reminder and praise recall. These strategies are pro-
actively, strategically and intensively integrated into
treatment-as-usual to support encoding. Memory sup-
port is delivered alongside each “treatment point,”
defined as a main idea, principle, or experience that the
treatment provider wants the patient to remember or
implement as part of the treatment [10]. We acknow-
ledge that some memory support is a standard part of
certain treatments, including CBT [84, 87]. In the
present study, the two treatment arms will differ in the
“dose” of memory support. An underpowered pilot study
indicated that the Memory Support Intervention
effectively increases the amount of memory support de-
livered and improves depression outcome on certain
measures [34].
Intervention fidelity
Treatment session video-recordings that occur at session
2 and at weeks 4, 8, 12 and 16 are coded using the
MSRS [78] to establish the dose of memory support de-
livered. CT +Memory Support therapists are blind to
which sessions are coded. CT-as-usual therapists are
blind to the memory support portion of the research.
To reduce expectations impacting the delivery of each
arm and to ensure purity of delivery [88], each treatment
provider will be allocated to deliver only one of the two
treatments. The rationale is that therapists report that
once they have mastered memory support it is difficult
to deliver CT-as-usual.
Clinicians use a treatment manual and receive weekly
supervision to standardize treatment administration.
Treatment sessions are video- and audio-taped and a
random selection are rated using the Cognitive Therapy
Rating Scale [89] which is a measure of general interven-
tion skills and CBT-specific skills. The goal of this inter-
vention is to maintain consistency and ensure adherence
to the protocols [89].
Data analysis
Preliminary data evaluation
Missing or aberrant data will be verified. Data will be
audited for quality and completeness. Evaluation of dis-
tributions detects outliers and ensures that assumptions
of planned analyses are met. Baseline differences be-
tween groups will be examined (e.g., IQ, demographics,
psychiatric and medical comorbidity, medications). Stat-
istical tests will not be used to select covariates in the
primary intent-to-treat analysis [90–92]. Instead, the
potential influences of baseline differences will be evalu-
ated as moderators. If remedial training is given to a
therapist whose adherence to the treatment protocol is
not satisfactory, this will be included as a dummy-coded
covariate in all analyses.
Multiple testing
We will use alpha = .05 for each primary hypothesis. For
multiple testing conducted within each main hypothesis,
we will adopt a stepwise multiple comparison procedure
that is considered more powerful than the widely used
Bonferroni correction [93, 94].
Missing data
Longitudinal analyses will use all available data and pro-
duce valid inferences if attrition depends on treatment
group or on previous outcomes for the same participant
[95]. If dropout is associated with other variables, they
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will be added as predictors to reduce bias due to data
missing not at random.
Hypothesis 1
CT +Memory Support will be superior to CT-as-usual
for improving course of illness and reducing functional
impairment at post-treatment, 6FU and 12FU on
primary outcomes listed in Additional file 1. Treatment
groups will be compared on categorical outcomes (e.g.,
remission, relapse) using logistic regression to evaluate
the odds of remission at post-treatment, and the odds of
relapse at 6FU and 12FU. For the continuous variables
(e.g., IDS-SR), we will test for differences in the mean
trajectories across time between CT +Memory Support
and CT-as-usual using Hierarchical Linear Modeling
(HLM) [96–98]. The 1st level will represent within-
person variation, and will include time indicators (or
dummy variables) as predictors (post-treatment, 6FU
and 12FU, with baseline as reference). The 2nd level rep-
resents between-person variation in the intercept and
coefficients of the time indicators, and will include a
dummy variable for arm (CT +Memory Support vs. CT-
as-usual) as the predictor variable. Interactions between
arm and the time indicators will be retained only if
found to be significant at the 5% level using likelihood-
ratio tests. Significant interaction terms between arm
and time indicator suggest that there are different trajec-
tories across time and between arms, and will be
graphed to interpret the interaction.
Hypothesis 2
Relative to CT-as-usual, the relationship between CT
+Memory Support and better treatment outcome will
be mediated by patient memory for treatment.
Outcome will be measured by IDS-SR at post-treatment,
6FU and 12FU. Patient memory will be measured by the
Patient Treatment Recall Task and the Generalization
Task at weeks 4, 8, 12 and 16 of treatment. A mediation
model will be specified using Structural Equation
Modeling [99]. Indirect effects from CT +Memory
Support to better treatment outcome via patient
memory will be assessed.
Hypothesis 3
The relationship between treatment condition and out-
come will be moderated by poorer response subgroups;
namely, older age, lower IQ, more chronic depression,
poorer baseline declarative memory performance and
fewer years of education. IQ will be estimated with the
NART. Chronicity will be defined as current episode
greater than or equal to 2 years [46]. Declarative mem-
ory will be quantified as described in Additional file 1.
To assess whether Memory Support is more beneficial
for any of the patient subgroups, moderation will be
tested as an interaction between potential moderator
and treatment arm; in the HLMs, the interaction be-
tween any of these variables, time, and treatment group
will be tested.
Intervention fidelity check
MSRS scores will be compared for CT +Memory Sup-
port vs. CT-as-usual via independent samples t tests. To
test the assumption that memory for CT session content
improves as a result of CT +Memory Support we will
use HLMs to analyze differences in linear rates of
change between the two groups on the Patient Treat-
ment Recall Task and Generalization Task delivered
during weeks 4, 8, 12 and 16 of the treatment phase and
at 6FU and 12FU.
Additional planned analyses
1. Is CT +Memory Support associated with longer time-
to-relapse relative to CT-as-usual? Survival analyses
[100] will be conducted. The Kaplan-Meier product
limit method will be used to generate survival curves
for the two treatment conditions [101]. Cox
regression will be applied to test for group
differences.
2. Are demographics, psychiatric and medical
comorbidity, medications and symptom severity
moderators? This will be tested by adding the
product of arm and the moderator variable to
regression models or HLMs [102, 103]. A significant
coefficient for the interaction term would indicate a
moderating effect, and will be followed up with
graphs to determine the nature of the effect
modification [102].
3. Does memory for treatment improve simply because
memory deficits resolve with successful treatment?
Linear regressions will evaluate whether change in
pre-post IDS and pre-post declarative and working
memory each independently predict week 4 to post-
treatment differences in Patient Recall Task per-
formance. If significant, we will conduct a
hierarchical linear regression to evaluate whether
pre-post change in IDS scores predicts pre-post
change in Patient Treatment Recall Task
performance beyond pre-post improvement in
memory.
4. Memory Support Rating Scale data will be used to
delineate the most effective types and combinations
of memory support. Factor analysis will be used to
test the structure of the Memory Support Rating
Scale based on Lee et al. [78]. Associations between
patient recall, depression outcomes, and memory
support variables will be assessed.
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5. Number of sessions received (range 20–26 sessions)
will be added as a covariate to control for differences
in this across participants.
Power analysis
Based on the pilot study [34], using Glimmpse [104,
105] for repeated measures design, we took into account
the four repeated measurements (pre-treatment, post-
treatment, 6FU, 12FU). At an alpha level of 0.05 with
80% power, the sample size is estimated to be 80 for the
IDS-SR. We also used G*Power and the Demidenko
[106] method to calculate estimated sample size for bin-
ary mood outcomes (i.e., remission, relapse). The sample
sizes are estimated to be 103 (remission) and 118 (re-
lapse). Finally, Fritz and MacKinnon [107] provide rec-
ommendations for mediation sample size, and estimates
from pilot data indicate that the recommended sample
size is 148. Adding an additional 20% for possible attri-
tion, we propose a sample of 178.
Discussion
This study protocol addresses several research priorities.
First, following the experimental therapeutics approach
[108], this study protocol describes a confirmatory effi-
cacy trial to provide a definitive test of the hypothesis
that a novel target—patient memory for the contents of
treatment—probed with a novel intervention—the Mem-
ory Support Intervention—will improve clinical out-
come. Second, a novel intervention derived from basic,
non-patient research in cognitive science and education,
will be tested in the service of improving outcomes for
patients with severe mental disorders. Third, the Mem-
ory Support Intervention has been derived to be
“transdiagnostic” (relevant to a broad range of mental
disorders) and “pantreatment” (relevant to a broad range
of types of treatment). However, investigating these pos-
sible broader applications seems premature without first
establishing efficacy, which is the aim of the study de-
scribed in this protocol. If the results are promising, fu-
ture directions will test the applicability to a broad range
of biopsychosocial interventions for a wide range of pa-
tient populations being treated at various medical and
mental health settings.
Trial status
The trial is funded for 4 years (Project ID Number:
R01MH108657). The research staff team started setting
up the study in September, 2016. Patients were first ran-
domized in December, 2016. The treatment phase will
be completed by August of 2019. Final outcome assess-
ments will be complete by August of 2020.
Endnotes
1This was added in July, 2017. NIH/NIMH data-
sharing requirements necessitated reconsent of
participants already randomized. If a patient does not
agree to data sharing we have been instructed to exclude
them from the analysis.
Additional files
Additional file 1: SPIRIT 2013 Checklist. (DOC 122 kb)
Additional file 2: Summary of primary and secondary outcome(s).
(DOCX 13 kb)
Additional file 3: Timeframe for Assessments. Table indicating time
points where assessments are conducted. (DOCX 46 kb)
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